Grail (NASDAQ:GRAL) Trading Down 6.7% - Should You Sell?

Grail, Inc. (NASDAQ:GRAL - Get Free Report)'s share price was down 6.7% during mid-day trading on Monday . The company traded as low as $18.05 and last traded at $18.29. Approximately 165,412 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 1,076,762 shares. The stock had previously closed at $19.60.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on GRAL shares. Wolfe Research initiated coverage on shares of Grail in a research report on Friday, November 15th. They issued a "peer perform" rating on the stock. Guggenheim started coverage on Grail in a report on Thursday, October 17th. They set a "neutral" rating on the stock. Finally, Morgan Stanley started coverage on Grail in a report on Wednesday, November 27th. They issued an "equal weight" rating and a $16.00 price objective for the company.

Grail Trading Down 4.9 %

The business's 50-day simple moving average is $17.10.

Insider Activity

In other news, major shareholder Chun R. Ding acquired 7,629 shares of the firm's stock in a transaction on Tuesday, October 1st. The stock was acquired at an average price of $13.52 per share, for a total transaction of $103,144.08. Following the completion of the acquisition, the insider now owns 3,503,655 shares in the company, valued at $47,369,415.60. This trade represents a 0.22 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Robert P. Ragusa sold 123,454 shares of the business's stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the sale, the chief executive officer now owns 612,661 shares in the company, valued at approximately $8,589,507.22. This trade represents a 16.77 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have purchased 58,829 shares of company stock valued at $757,298.

Grail Company Profile

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.